Cell Therapeutics Files for Special Protocol Assessment for pixantrone in relapsed indolent non-Hodgkin ‘s lymphoma Cell Therapeutics announced today that it has submitted for a Special Protocol Assessment with the U.S comprare il Kamagra . Food and Drug Administration for the design of the phase III trial of pixantrone for patients with indolent non-Hodgkin ‘s lymphoma . To examine the to examine the complete remission rates and time to disease progression of the combination treatment of fludarabine, pixantrone and rituximab in the treatment of patients who have failed to five previous treatment for relapsed or refractory indolent NHL. The study is expected to include 300 patients. – The impressive complete remission rates and durable survival data in our phase II combination study for indolent NHL patients reasons for conducting reasons for conducting a Phase III clinical trial , and we look forward to feedback and guidance from the FDA about the study Design, said James A. President and CEO of CTI. Pixantrone has activity in both activity in both indolent and aggressive NHL especially in the relapsed setting, paving the way for a possible registration across both types of NHL thus potentially doubling the size of the market potential in lymphoma. .
Depression occurs for several reasons. In some people, depression and heart disease reflect a genetic vulnerability both conditions both conditions. Depression, which first appears after a heart attack may represent fear of dying or grief over the loss of health. Fear and grief do not necessarily respond to the same treatment strategies, so figuring out the cause of the problem to find the right finding the right treatment. – The ‘Harvard Heart Letter ‘notes that breaking out of depression on your own can be hard. Standard treatment includes talk therapy and medication. If these do not help, ask your doctor for a referral to a therapist who can help sort your thoughts and hit on a particular treatment. Continue reading